Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 14Gynecologic 7Gastrointestinal 5Other solid neoplasm 3CNS 3Breast 3Other hematologic neoplasm 2Genitourinary 2Sarcoma 1NET 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 36Everolimus 32pembrolizumab 24Temozolomide 21Magnetic Resonance Spectroscopy 21Nivolumab 18lenvatinib 17gallium Ga 68 dotatate 16cabozantinib 15Cisplatin 15lanreotide 143-Iodobenzylguanidine 14Capecitabine 13trametinib 12dabrafenib 12Bevacizumab 12Octreotide 11Surveys and Questionnaires 10Surgical Procedures, Operative 10Sunitinib 10Radiosurgery 10Positron Emission Tomography Computed Tomography 10Blood Specimen Collection 10Sorafenib 9Paclitaxel 9Ipilimumab 9Carboplatin 9surufatinib 8Etoposide 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × nintedanib × Endocrine × Clear all
NCT02399215 2023-12-26

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Roswell Park Cancer Institute

Phase 2 Completed
32 enrolled 12 charts
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡